Review article · 2016
Review articlePublished 2016
Can Translational Medicine Exploit the Reported
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
In the early 1950s, 2 scientists considered the making of progress in cancer research. One of them was Arnott, a Harveian Orator, who promoted the view that, if the metastatic pattern appears to be anomalous, it is a pointer to the direction to take in remedial researching. Another giant was Professor Cameron, who delivered a Memorial Lecture on the liver which is now enmeshed in the anomaly viewed as “metastatic inefficiency.” As he posited, hypotheses should be formulated to explain such matters even if the outcome seems hopeless. As regards the liver itself, I had illustrated the anomalous patterns and offered an explanation based on the spatial distribution of its discrete secondary deposits. This time, the emphasis is on careful case reports because they graphically confirm the formulated theoretical concepts. As a follow-up, the effective role of the newly named “Erythrocyte Associated Necrosis Factor” (EANF) has been entertained. In all probability, if adequate searchlight is beamed on EANF through the well funded field of translational medicine, breakthroughs ought to arise as regards target therapy. Moreover, this could conduce to cancer cure sooner than later.
Subjects
General & Internal MedicineAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Commentary · 2015
What is the Possible Role of Stem Cells in the Proposed “Erythrocyte Associated Necrosis Factor” Exploitable in Translational Medicine
Commentary · 2015
What is the Possible Role of Stem Cells in the Proposed and#8220;Erythrocyte Associated Necrosis Factorand#8221; Exploitable in Translational Medicine
Short communication · 6 Oct 2020
Translational Medicine 2015: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: An early phase IIa trial report - Wei-Dong Han - Chinese PLA General Hospital
Commentary · 4 Apr 2022
Note on Cancer Therapy by Using Translational Medicine
More from this journal
The newest in Translational Medicine.
Opinion · 25 Jun 2026
Radiomics in Translational Medicine for Quantitative Imaging and Personalized Clinical Assessment
Opinion · 25 Jun 2026
Digital Twin Technology in Translational Medicine for Individualized Disease Simulation and Clinical Planning
Opinion · 25 Jun 2026
Proteomic Signatures in Translational Medicine for Disease Stratification and Therapeutic Evaluation
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalTranslational Medicine
- SubjectGeneral & Internal Medicine
- BylineArticles whose byline prints “Onuigbo WIB”

